Prognosis of a series of 763 consecutive node-negative invasive breast cancer patients without adjuvant therapy: Analysis of clinicopathological prognostic factor

Journal of Surgical Oncology

Volumn 71, Issue 2, 1999, Pages 101-105

  Saimura, Michiyo ^a   Fukutomi, Takashi ^a   Tsuda, Hitoshi ^b   Sato, Hiroshi ^a   Miyamoto, Kazuaki ^a   Akashi Tanaka, Sadako ^a   Nanasawa, Takeshi ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

Breast cancer; Histological grade; Lymph node metastasis; Prognostic factor

Indexed keywords

ESTROGEN RECEPTOR; HORMONE RECEPTOR; PROGESTERONE RECEPTOR;

ADJUVANT THERAPY; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER GRADING; CONTROLLED STUDY; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPH NODES; MASTECTOMY; MIDDLE AGED; NEOPLASM INVASIVENESS; PROGNOSIS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SURVIVAL RATE;

EID: 0033026633     PISSN: 00224790     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9098(199906)71:2<101::AID-JSO8>3.0.CO;2-G     Document Type: Article

References (15)

1. Goldhirsh A, Wood WC, Senn HJ, et al.: Meeting highlights: International consensus panel on the treatment of primary breast cancer. J Natl Cancer Inst 1995;87:1441-1445.
2. Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women (Review). Lancet 1992; 339:1-15.
3. Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 1992;339:71-85.
4. Allen DS, Bulbrook MA, Hayward JL, et al.: Recurrence and survival rates in British and Japanese women with breast cancer. Breast Cancer Res Treat 1991;18(Suppl 1):S131-134.
5. Fukutomi T: Breast carcinoma-counterpoint. In Johnson FE, Virgo KS (eds): "Cancer Patient Follow-Up." St. Louis: Mosby, 1997:315-319.
6. Tsuda H, Hirohashi S, Shimosato Y, et al.: Correlation between histologic grade of malignancy and copy number of c-erbB-2 gene in breast carcinoma. Cancer 1990;65:1794-1800.
7. Watanabe T, Wu JZ, Morikawa K, et al.: In vitro sensitivity test of breast cancer cells to hormonal agents in a radionucleotide-incorporation assay. Jpn J Cancer Res 1990;81:536-543.
8. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
9. Peto R, Peto J: Asymptomatically efficient rank invariant test procedures. J R Stat Soc [A] 1972;135:185-198.
10. Tsuda H, Iwaya K, Fukutomi T, et al.: p53 mutations and c-erbB-2 amplifcation in intraductal and invasive breast carcinomas of high histologic grade. Jpn J Cancer Res 1993;84:394-401.
11. Tsuda H, Sakamaki C, Tsugane S, et al.: Prognostic significance of accumulation of gene and chromosome alterations and histological grade in node-negative breast carcinoma. Jpn J Clin Oncol 1998;28:5-11.
12. Tominaga S, Kuroishi T: Epidemiology of breast cancer in Japan. Breast Cancer 1995;2:1-7.
13. Iwaya K, Tsuda H, Fukutomi T, et al.: Histologic grade and p53 immunoreaction as indicators of early recurrence of node-negative breast cancer. Jpn J Clin Oncol 1997;27:6-12.
14. Fukutomi T, Akashi-Tanaka S, Nanasawa T, et al.: Adjuvant six cycles of high-dose adriamycin, cyclophosphamide, methotrexate, 5-fluorouracil (ACMF) vs. 12 cycles of low-dose ACMF with tamoxifen for premenopausal, node-positive breast cancer patients: Results of a prospective randomized study. J Surg Oncol 1995;60:242-246.
15. National Surgical Adjuvant Study Group (Japan): Phase III randomized comparison of postoperative adjuvant chemotherapy with 2-year oral UFT (uracil/tegafur) versus six-cycle CMF (cyclosphophamide/methotrexate/5-fluorouracil) in high-risk node-negative breast cancer patients. Jpn J Clin Oncol 1998;28:77-80.